Bruce Booth - 01 Mar 2022 Form 4 Insider Report for Vigil Neuroscience, Inc. (VIGL)

Role: Director
Signature: /s/ Ommer Chohan, Attorney-in-Fact
Issuer symbol: VIGL
Transactions as of: 01 Mar 2022
Net transactions value: +$72,967
Form type: 4
Filing time: 03 Mar 2022, 15:05:54 UTC
Previous filing: 11 Jan 2022
Next filing: 10 Jun 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIGL	Stock Option Grant (Right to Buy)	Award	$72,967	+7,577		$9.63	7,577	01 Mar 2022	Common Stock	7,577	$16.13	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This option was awarded to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation. The shares subject to this option shall vest and become exercisable in four equal quarterly installments on the last day of each calendar quarter, with the first installment vesting on March 31, 2022.
F2	This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.

Content

This option was awarded to the reporting person pursuant to the Issuer's Non-Employee Director Compensation Policy in lieu of cash compensation. The shares subject to this option shall vest and become exercisable in four equal quarterly installments on the last day of each calendar quarter, with the first installment vesting on March 31, 2022.

This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.